Lighthouse Investment Partners LLC Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Lighthouse Investment Partners LLC purchased a new stake in Grifols, S.A. (NASDAQ:GRFSFree Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 72,857 shares of the biotechnology company’s stock, valued at approximately $842,000.

Several other hedge funds have also modified their holdings of GRFS. Jump Financial LLC acquired a new stake in shares of Grifols in the 3rd quarter valued at approximately $136,000. QRG Capital Management Inc. acquired a new position in Grifols during the third quarter worth $303,000. Black Creek Investment Management Inc. raised its holdings in Grifols by 16.4% during the third quarter. Black Creek Investment Management Inc. now owns 9,574,388 shares of the biotechnology company’s stock worth $87,510,000 after purchasing an additional 1,351,000 shares during the last quarter. Wolverine Asset Management LLC acquired a new position in Grifols during the third quarter worth $419,000. Finally, Brandes Investment Partners LP raised its holdings in Grifols by 8.2% during the third quarter. Brandes Investment Partners LP now owns 11,061,281 shares of the biotechnology company’s stock worth $101,100,000 after purchasing an additional 835,253 shares during the last quarter.

Grifols Stock Performance

GRFS stock opened at $7.11 on Tuesday. The stock has a 50-day moving average price of $6.96 and a two-hundred day moving average price of $7.98. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.79 and a quick ratio of 1.29.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft cut Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th.

View Our Latest Stock Report on Grifols

Grifols Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Recommended Stories

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.A. (NASDAQ:GRFSFree Report).

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.